ADCT NYSE
ADC Therapeutics S.A.
1W: +1.8%
1M: -16.4%
3M: -16.6%
YTD: -2.8%
1Y: +59.1%
3Y: +40.2%
5Y: -83.9%
$3.39
-0.01 (-0.29%)
Weekly Expected Move ±5.5%
$3
$3
$3
$3
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$81M
+14.9% ▲
Gross Profit
$74M
+13.6% ▲
Operating Income
-$108M
+17.0% ▲
Net Income
-$143M
+9.6% ▲
EPS (Diluted)
$-1.12
+30.9% ▲
EBITDA
-$107M
-3.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $34M | $210M | $70M | $71M | $81M |
| YoY Growth | +0.0% | +518.9% | -66.9% | +1.8% | +14.9% |
| Cost of Revenue | $1M | $3M | $3M | $6M | $8M |
| Gross Profit | $33M | $207M | $67M | $65M | $74M |
| Gross Margin | 95.9% | 98.4% | 96.4% | 91.6% | 90.6% |
| R&D Expenses | $158M | $186M | $127M | $110M | $104M |
| SG&A Expenses | $136M | $143M | $106M | $86M | -$7M |
| Operating Expenses | $294M | $330M | $233M | $196M | $182M |
| Operating Income | -$262M | -$123M | -$166M | -$131M | -$108M |
| Operating Margin | -771.6% | -58.8% | -238.6% | -184.4% | -133.2% |
| Interest Expense | $18M | $37M | $46M | $50M | $52M |
| Income Before Tax | -$252M | -$157M | -$201M | -$158M | -$143M |
| Tax Expense | -$21M | $227K | $39M | $166K | -$157K |
| Net Income | -$230M | -$157M | -$240M | -$158M | -$143M |
| Net Margin | -678.2% | -74.9% | -345.1% | -222.8% | -175.3% |
| EPS (Diluted) | $-3.00 | $-1.99 | $-2.94 | $-1.62 | $-1.12 |
| EBITDA | -$231M | -$108M | -$146M | -$103M | -$107M |
| Shares Outstanding | 77M | 78M | 82M | 97M | 127M |